Table 2.
Cancer- and chemotherapy-induced nausea and vomiting (CINV)-related quality of life (QoL), cancer-related fatigue, and nutrition status.
| Cycle 1 | Cycle 2 | Cycle 3 | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total | Placebo | Intervention | p Value | Total | Placebo | Intervention | p Value | Total | Placebo | Intervention | p Value | |
| CINV-QoL | 123 (103, 126) | 111 (99, 126) | 124.5 (113.2, 126) | 0.043 * | 124 (108, 126) | 117 (109, 126) | 124 (108, 126) | 0.916 | 122 (107, 126) | 120 (111, 126) | 123.5 (107, 126) | 0.931 |
| Nausea-related QoL | 60 (51, 63) | 54 (46, 63) | 61.5 (56.2, 63) | 0.029 * | 61 (49, 63) | 56 (49, 63) | 61 (52.2, 63) | 0.494 | 56 (49, 63) | 56 (49, 63) | 56.5 (46.7, 63) | 0.931 |
| Vomiting-related QoL | 63 (51, 63) | 63 (51, 63) | 63 (54, 63) | 0.237 | 63 (51.9, 63) | 63 (52, 63) | 63 (54.7, 63) | 0.663 | 63 (51, 63) | 63 (54, 63) | 59 (50.2, 63) | 0.414 |
| Global cancer-related QoL | 78.1 ± 19.5 | 71.9 ± 18.3 | 85.1 ± 18.9 | 0.015 * | 71.1 ± 14.5 | 67.6 ± 10.2 | 74.9 ± 17.7 | 0.077 | 79.1 ± 14.9 | 75 ± 13.8 | 83.6 ± 15 | 0.040 * |
| Fatigue | 36.7 ± 12.8 | 32.2 ± 10.8 | 41.8 ± 13 | 0.006 * | 36.1 ± 9.4 | 34.5 ± 7.9 | 37.7 ± 10.8 | 0.23 | 39.1 ± 9.2 | 36.1 ± 7.2 | 42.4 ± 10.2 | 0.013 * |
| Nutrition status at start of cycle (n, well nourished) | 44 | 22 | 22 | 0.371 | 38 | 19 | 19 | 0.500 | 37 | 19 | 18 | 0.622 |
Normally distributed measures were presented as mean ± standard deviation and non-normally distributed measures were presented as median (25th percentile, 75th percentile). * signifies a statistically significant result (p < 0.05)